PlainRecalls
FDA Drug Moderate Class II Ongoing

Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06

Reported: November 26, 2025 Initiated: October 23, 2025 #D-0159-2026

Product Description

Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06

Reason for Recall

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.

Details

Units Affected
36,624 bottles
Distribution
Nationwide in the USA
Location
Pennington, NJ

Frequently Asked Questions

What product was recalled?
Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06. Recalled by Zydus Pharmaceuticals (USA) Inc. Units affected: 36,624 bottles.
Why was this product recalled?
Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.
Which agency issued this recall?
This recall was issued by the FDA Drug on November 26, 2025. Severity: Moderate. Recall number: D-0159-2026.